An experimental oral antiviral from Pfizer will be the focus of a Phase 1 study involving healthy adults.
Known as PF-07321332, the drug has shown promise during in vitro studies against SARS-CoV-2.
PF-07321332 belongs to a class of drugs known as protease inhibitors, which are commonly used to treat HIV/AIDS and hepatitis C. Protease inhibitors bind to a viral enzyme known as protease to stop viral replication.
Pfizer believes PF-07321332 to be the first orally-administered SARS-CoV-2-specific investigational protease inhibitor to be studied in a clinical trial.
Get the full story from our sister site, Drug Discovery & Development.